Patient Advocates Take Aim at Progression in Myeloproliferative Neoplasms Following up on a promise to invest in research that would lead to better understanding and prevention of progression from PV/ET to MF, the MPN Research Foundation has made its first strategic investment in this area with a one-year grant to Dr. Ann Mullally at Dana-Farber… Read More »PATIENT ADVOCATES TAKE AIM AT PROGRESSION IN MYELOPROLIFERATIVE NEOPLASMS
Breaking News Although it is not indicated for MPNs, people with Polycythemia Vera, Essential Thrombocythemia or Myelofibrosis sometimes take a form of interferon for their MPN. PEGASYS is a pegylated form of interferon manufactured by Genentech. We have previously reported stories of how people with an MPN have dealt with issues related to access and… Read More »PEGASYS USERS MAY NOW ACCESS RESOURCES TO HELP WITH REIMBURSEMENT ISSUES THROUGH GENENTECH
Aug. 29, 2019 TOPIC: Advocacy, Featured News, Get Involved Mark Your Calendars – October 1 is Rare Cancer Day! Posted by Laura Mullen Washington, DC, August 29, 2019–The National Organization for Rare DisordersⓇ (NORD) has announced a day devoted to raising awareness about rare cancers. Spearheaded by the NORD Rare Cancer Coalition, which is comprised of 24 rare… Read More »MARK YOUR CALENDARS – OCTOBER 1 IS RARE CANCER DAY!
Researchers recently published an article, “Addressing and proposing solutions for unmet clinical needs in the management of myeloproliferative neoplasm-associated thrombosis: A consensus-based position paper,” resulting from a group discussion among an ad hoc constituted Panel of experts aimed at highlighting unmet clinical needs in the management of thrombotic risk and thrombotic events associated with myeloproliferative neoplasms… Read More »ADDRESSING AND PROPOSING SOLUTIONS FOR UNMET CLINICAL NEEDS IN THE MANAGEMENT OF MYELOPROLIFERATIVE NEOPLASM
“BREAKING NEWS: The FDA has approved fedratinib as a new treatment option for myelofibrosis patients. Watch now as our Editorial and Community Director, Rebecca Seago-Coyle, sits down with Dr. Ruben Mesa, Director of Mays Cancer Center at UT Health San Antonio MD Anderson, to talk about what this approval means for myelofibrosis patients, how to… Read More »PATIENT POWER INTERVIEWS DR. RUBEN MESA ABOUT FEDRATINIB APPROVAL
An article published in Clinical Cancer Research, “Aurora Kinase A Inhibition Provides Clinical Benefit, Normalizes Megakaryocytes, and Reduces Bone Marrow Fibrosis in Patients with Myelofibrosis: A Phase I Trial,” determined that targeting the Aurora Kinase A Inhibition has potential benefit for patients with myelofibrosis. “Conclusions: Given the limitations of ruxolitinib, novel therapies are needed for myelofibrosis. In this… Read More »CLINICAL CANCER RESEARCH PUBLISHES ARTICLE ON MYELOFIBROSIS
In an article published by Targeted Oncology, Dr. Srdan Verstovsek, MD, Ph.D., discussed with a group of physicians the considerations he makes with the diagnosis and management of patients with myeloproliferative neoplasms (MPNs). Read Dr. Verstovsek’s answers to questions such as, what are important diagnostic parameters of myelofibrosis, how do you treat patients with MDS/MPN, what is the best… Read More »VERSTOVSEK OUTLINES FEATURES OF AND THERAPIES FOR MYELOPROLIFERATIVE NEOPLASMS
“Background: Janus Kinase 2 (JAK2) plays pivotal roles in signaling by several cytokine receptors. The mutant JAK2 V617F is the most common molecular event associated with myeloproliferative neoplasms. Selective targeting of the mutant would be ideal for treating these pathologies by sparing essential JAK2 functions.” CLICK HERE TO LEARN MORE
In an article published in nature: International Journal of Science, researchers investigated a method for detecting mutations and measuring gene expression in individual blood progenitor cells. The ‘decision’ that progenitor cells make as to which cell type to become is generally determined by the signals that they receive from their immediate surroundings. However, mutations that… Read More »HOW MUTATIONS EXPRESS THEMSELVES IN BLOOD-CELL PRODUCTION
Presented at the 24th Congress of the European Hematology Association (EHA), Imago BioSciences, Inc. announced today that positive safety and early efficacy clinical data was proven during their Phase 1/2a clinical trial of a lysine-specific demethylase (LSD1) inhibitor, IMG-7289. Imago decided to expand the study into a Phase 2b trial and is evaluating clinical investigations in additional myeloid diseases. “IMG-7289 has… Read More »IMAGO BIOSCIENCES TO EXPAND CLINICAL TRIAL OF IMG-7829 FOR MF PATIENTS
